Drugs / Prednisone/prednisolone
Trials 0
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04599634 Background | Dec 2021 → Mar 2024 | chronic lymphocytic leukemia/small lymphocytic lymphoma, follicular lymphoma, mantle cell lymphoma, marginal zone lymphoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Prednisone/prednisolone | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04599634 ↗ |
| Route | Intravenous | “100mg intravenous prednisone/prednisolone” NCT04599634 ↗ |